Laryngeal Dystonia
18
9
10
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (18)
Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
Brain Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia
Effects of Neuromodulation in Laryngeal Dystonia
tDCS for Laryngeal Dystonia
Monitoring of the Safety and the Performance of the Endoscopic Cap Electrode (ECE50)
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
Brain-Computer Interfaces in Laryngeal Dystonia
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
Imaging Genetics of Laryngeal Dystonia
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
Deep Brain Stimulation for Laryngeal Dystonia: From Mechanism to Optimal Application
Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia
Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia
Cortical Silent Period in Laryngeal Dystonia
Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine
Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
rTMS in Spasmodic Dysphonia
Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change